Adverse drug reaction patterns of <scp>GLP</scp> ‐1 receptor agonists approved for obesity treatment: Disproportionality analysis from global pharmacovigilance database
Our findings emphasize the need for cautious prescribing and further research to ensure the safe use of these medications.
Authors
- Jaeyu Park (ORCID: https://orcid.org/0009-0005-2009-386X)
- Kyeongmin Lee
- Hyesu Jo (ORCID: https://orcid.org/0009-0004-1895-300X)
- Hayeon Lee (ORCID: https://orcid.org/0009-0000-2403-6241)
- Dong Keon Yon (ORCID: https://orcid.org/0000-0003-1628-9948)
- Jaehyeong Cho (ORCID: https://orcid.org/0000-0001-7213-5033)
- Tae Hyeon Kim (ORCID: https://orcid.org/0000-0002-9723-2136)
- Xuerong Wen (ORCID: https://orcid.org/0000-0002-4803-7895)
- Sunyoung Kim (ORCID: https://orcid.org/0000-0002-1736-9088)
- Seoyoung Park (ORCID: https://orcid.org/0009-0008-4115-2947)
- Jiyeon Oh (ORCID: https://orcid.org/0009-0005-3291-4370)
- Hanseul Cho (ORCID: https://orcid.org/0009-0005-7463-4094)
Institutions
- Harvard University (US)
- University of Rhode Island (US)
- Kyung Hee University (KR)
- Kyung Hee University Medical Center (KR)
- CHA University (KR)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-04-02
- DOI
- https://doi.org/10.1111/dom.16376
- Citations
- 10
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 13.07
Funders
- World Health Organization
- National Research Foundation
- National Research Foundation of Korea
- Iran Telecommunication Research Center
- Ministry of Science and ICT, South Korea
- Institute for Information and Communications Technology Promotion